Rosiglitazone label and medication guide updated with cardiovascular risks
FDA has announced that the physician labeling and patient medication guide for rosiglitazone (Avandia, GlaxoSmithKline) have been changed to include information on cardiovascular risks (including death) of this agent.
FDA has announced that the physician labeling and patient medication guide for rosiglitazone (Avandia, GlaxoSmithKline) have been changed to include information on cardiovascular risks (including death) of this agent.
In addition, labeling has been revised to state that rosiglitazone and rosiglitazone-containing medications should only be used in patients already being treated with these agents, or in patients whose serum glucose levels cannot be controlled with other anti-diabetic medicines and who, after consulting with their healthcare provider, do not wish to use pioglitazone-containing medicines (Actos, Actoplus Met, Actoplus Met XR, or Duetact). Rosiglitazone is also sold as a combination product under the brand name Avandamet (rosiglitazone and metformin) and under the brand name Avandaryl (rosiglitazone and glimepiride).
In late September 2010, FDA announced that it would significantly restrict the use of rosiglitazone-containing medicines to patients with type 2 diabetes who cannot control their serum glucose levels with other medications. These new restrictions came about as a response to data that suggested an elevated risk of myocardial infarction in patients treated with rosiglitazone.
The Risk Evaluation and Mitigation Strategy (REMS) that will restrict the availability of medications containing rosiglitazone has not yet been approved or formally implemented. FDA expects to approve the REMS by spring 2011, and the manufacturer to complete implementation 6 months thereafter.
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
